New Alstom lawsuit challenges waivers granted by Federal Railroad Administration for construction of new Brightline West ...

Eurostar itself links London, Paris, Amsterdam and Brussels in its network, using primarily multi-unit Siemens Velaro e320 trains, a nod to their 320 km/h or 200 mph top speed. My journey to London ...

Siemens emite título digital de US$ 331 milhões ... Fund da BlackRock. Este novo índice permite que traders acessem o fundo por meio de instrumentos financeiros on-chain e rastreia o ...

Update: Adds company statement about Ozempic availability in the U.S. Novo Nordisk (NVO) has said in a note published by the European Medicines Agency that the supply shortage of its diabetes drug ...

Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. Still ...

Novo Nordisk's (NYSE: NVO) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the ...

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to ...

Localizado em Alfragide, o novo i-Experience Center 4.0 é o primeiro de uma rede que a Siemens que criar para apoiar o desenvolvimento de projetos que suportem a digitalização na indústria. O centro ...

However, other studies have reached the opposite conclusion. Novo Nordisk's crown jewel is safe for now, and continues to drive its financial results higher. However, various potential headwinds ...

NBC News' Meagan Fitzgerald sits down with Novo Nordisk CEO Lars Jorgenson in Denmark to discuss the high costs and limited supply of the company's popular weight loss drugs, Ozempic and Wegovy ...

The diabetes medicine Ozempic has been a veritable cash cow for Novo Nordisk (NYSE: NVO). The company's revenue, earnings, and stock price have been on a tear in recent years -- and no single drug ...